GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001810514 | Oral cavity | EOLP | peptidyl-serine phosphorylation | 84/2218 | 315/18723 | 3.32e-13 | 1.05e-10 | 84 |
GO:001820914 | Oral cavity | EOLP | peptidyl-serine modification | 87/2218 | 338/18723 | 1.07e-12 | 2.46e-10 | 87 |
GO:000276413 | Oral cavity | EOLP | immune response-regulating signaling pathway | 108/2218 | 468/18723 | 4.04e-12 | 7.34e-10 | 108 |
GO:190165323 | Oral cavity | EOLP | cellular response to peptide | 85/2218 | 359/18723 | 2.06e-10 | 2.06e-08 | 85 |
GO:001657023 | Oral cavity | EOLP | histone modification | 98/2218 | 463/18723 | 5.58e-09 | 2.96e-07 | 98 |
GO:002241121 | Oral cavity | EOLP | cellular component disassembly | 94/2218 | 443/18723 | 1.00e-08 | 4.89e-07 | 94 |
GO:004343424 | Oral cavity | EOLP | response to peptide hormone | 89/2218 | 414/18723 | 1.29e-08 | 6.11e-07 | 89 |
GO:003286922 | Oral cavity | EOLP | cellular response to insulin stimulus | 53/2218 | 203/18723 | 1.65e-08 | 7.43e-07 | 53 |
GO:007137523 | Oral cavity | EOLP | cellular response to peptide hormone stimulus | 68/2218 | 290/18723 | 1.98e-08 | 8.62e-07 | 68 |
GO:003286823 | Oral cavity | EOLP | response to insulin | 62/2218 | 264/18723 | 7.78e-08 | 2.76e-06 | 62 |
GO:004312223 | Oral cavity | EOLP | regulation of I-kappaB kinase/NF-kappaB signaling | 58/2218 | 249/18723 | 2.72e-07 | 8.22e-06 | 58 |
GO:001821015 | Oral cavity | EOLP | peptidyl-threonine modification | 35/2218 | 125/18723 | 7.33e-07 | 1.85e-05 | 35 |
GO:000724924 | Oral cavity | EOLP | I-kappaB kinase/NF-kappaB signaling | 62/2218 | 281/18723 | 8.00e-07 | 2.02e-05 | 62 |
GO:001810715 | Oral cavity | EOLP | peptidyl-threonine phosphorylation | 33/2218 | 116/18723 | 1.02e-06 | 2.51e-05 | 33 |
GO:00027683 | Oral cavity | EOLP | immune response-regulating cell surface receptor signaling pathway | 66/2218 | 315/18723 | 2.44e-06 | 5.45e-05 | 66 |
GO:000828615 | Oral cavity | EOLP | insulin receptor signaling pathway | 32/2218 | 116/18723 | 3.06e-06 | 6.70e-05 | 32 |
GO:00510811 | Oral cavity | EOLP | nuclear envelope disassembly | 8/2218 | 11/18723 | 4.54e-06 | 9.41e-05 | 8 |
GO:00024292 | Oral cavity | EOLP | immune response-activating cell surface receptor signaling pathway | 60/2218 | 291/18723 | 1.16e-05 | 2.00e-04 | 60 |
GO:00027572 | Oral cavity | EOLP | immune response-activating signal transduction | 60/2218 | 291/18723 | 1.16e-05 | 2.00e-04 | 60 |
GO:00303971 | Oral cavity | EOLP | membrane disassembly | 8/2218 | 12/18723 | 1.22e-05 | 2.09e-04 | 8 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PRKCB | SNV | Missense_Mutation | rs767640161 | c.1774N>T | p.Arg592Cys | p.R592C | P05771 | protein_coding | deleterious(0.01) | possibly_damaging(0.877) | TCGA-A8-A091-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | PD |
PRKCB | SNV | Missense_Mutation | | c.927N>C | p.Lys309Asn | p.K309N | P05771 | protein_coding | tolerated(0.14) | benign(0.013) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
PRKCB | SNV | Missense_Mutation | | c.1834N>C | p.Glu612Gln | p.E612Q | P05771 | protein_coding | tolerated(0.18) | benign(0.287) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
PRKCB | SNV | Missense_Mutation | novel | c.371N>C | p.Gly124Ala | p.G124A | P05771 | protein_coding | deleterious(0) | probably_damaging(0.98) | TCGA-AC-A6IW-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PRKCB | SNV | Missense_Mutation | rs747105951 | c.586N>A | p.Val196Ile | p.V196I | P05771 | protein_coding | tolerated(0.07) | benign(0.345) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
PRKCB | SNV | Missense_Mutation | | c.1007G>A | p.Arg336Gln | p.R336Q | P05771 | protein_coding | tolerated(0.14) | benign(0.003) | TCGA-AR-A1AW-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | docetaxel | SD |
PRKCB | SNV | Missense_Mutation | | c.1526N>T | p.Ala509Val | p.A509V | P05771 | protein_coding | deleterious(0.02) | probably_damaging(0.999) | TCGA-BH-A0HB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD |
PRKCB | SNV | Missense_Mutation | rs775118763 | c.2008N>A | p.Glu670Lys | p.E670K | P05771 | protein_coding | tolerated_low_confidence(0.63) | benign(0.157) | TCGA-BH-A5J0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PRKCB | SNV | Missense_Mutation | | c.1093G>A | p.Asp365Asn | p.D365N | P05771 | protein_coding | deleterious(0.01) | benign(0.067) | TCGA-D8-A1JN-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozolum | SD |
PRKCB | SNV | Missense_Mutation | | c.827N>T | p.Lys276Met | p.K276M | P05771 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-E9-A1RF-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5579 | PRKCB | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, TRANSPORTER | | BRYOSTATIN | BRYOSTATIN | |
5579 | PRKCB | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, TRANSPORTER | inhibitor | 178102647 | | |
5579 | PRKCB | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, TRANSPORTER | | atenolol | ATENOLOL | |
5579 | PRKCB | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, TRANSPORTER | | Sotrastaurin acetate | | |
5579 | PRKCB | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, TRANSPORTER | | BISINDOLYLMALEIMIDE IX | BISINDOLYLMALEIMIDE IX | 25058929 |
5579 | PRKCB | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, TRANSPORTER | inhibitor | 249565629 | SOTRASTAURIN | |
5579 | PRKCB | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, TRANSPORTER | | dexmedetomidine | DEXMEDETOMIDINE | |
5579 | PRKCB | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, TRANSPORTER | | INGENOL MEBUTATE | | |
5579 | PRKCB | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, TRANSPORTER | inhibitor | 178101880 | | |
5579 | PRKCB | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, TRANSPORTER | inhibitor | CHEMBL494089 | GSK-690693 | |